BioCentury
ARTICLE | Company News

Warner Chilcott, P&G deal

August 31, 2009 7:00 AM UTC

Warner Chilcott acquired the global pharmaceuticals business of Procter & Gamble for $3.1 billion in cash. The deal includes P&G's marketed drugs Asacol HD mesalamine tablets to treat ulcerative colitis (UC); Actonel risedronate for osteoporosis; and the co-promotion rights to Enablex darifenacin to treat overactive bladder (OAB). P&G co-promotes Enablex with Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland). Warner Chilcott also acquired P&G's R&D pipeline and manufacturing facilities in Puerto Rico and Germany. Warner Chilcott said it will develop P&G's Intrinsa transdermal testosterone patch to treat sexual dysfunction in the U.S. Intrinsa is approved in the EU to treat hypoactive sexual desire disorder (HSDD) in women who have their uterus and both ovaries removed. ...